Cofactors that may influence vaccine responses

Current Opinion in HIV and AIDS

Volumn 5, Issue 5, 2010, Pages 404-408

  De Bruyn, Guy ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

coinfection; demographic factors; HIV; vaccine

Indexed keywords

BIOLOGICAL FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADENOVIRUS 5; AGE; BACTERIAL INFECTION; BODY MASS; CELLULAR IMMUNITY; CLINICAL TRIAL; DEMOGRAPHY; DRUG RESPONSE; ENVIRONMENTAL FACTOR; HEREDITY; HLA SYSTEM; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; INNATE IMMUNITY; KIDNEY FAILURE; LIVER FAILURE; MIXED INFECTION; NONHUMAN; NUTRITIONAL STATUS; PARASITOSIS; PRIORITY JOURNAL; RACE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; VECTOR CONTROL; VIRUS INFECTION;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; DEMOGRAPHY; GENETIC VARIATION; HUMANS; TREATMENT OUTCOME;

EID: 77955511169     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833d1fca     Document Type: Review

References (58)

1. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. J Am Med Assoc 1994; 271:698-702.
2. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clin Infect Dis 1995; 20:982-991.
3. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988; 2:467-470.
4. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999; 67:6341-6345.
5. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399-2410.
6. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting antivector immunity. Nature 2006; 441:239-243.
7. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77:6305-6313. (Pubitemid 36588400)
8. Fitzgerald JC, GaoGP, Reyes-Sandoval A, et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003; 170:141 61422.
9. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996; 219:220-227.
10. Abbink P, Lemckert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654-4663.
11. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
12. McElrath MJ, De RosaSC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
13. Corey L, McElrath MJ, Kublin JG. Poststep modifications for research on HIV vaccines. AIDS 2009; 23:3-8.
14. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does. not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009; 15:876-878.
15. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Experiment Med 2008; 205:271 7-2725.
16. Koup RA, Lamoreaux L, Zarkowsky D, et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 2009; 83:6318-6322.
17. McCoy K, Tatsis N, Korioth-Schmitz B, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of non-human primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol 2007; 81:6594-6604.
18. Cheng C, Gall JG, Nason M, et al. Differential specificity and immunogenicity. of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 2010; 84:630-638.
19. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25:3066-3069.
20. Van Loveren H, Van Amsterdam JG, Vandebriel RJ, et al. Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors. Environ Health Perspect 2001; 109:757-764.
21. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008; 26 (29-30):3551-3555.
22. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. J Am Med Assoc 1999; 282:331-340.
23. Mitka M. Critics bash HIV vaccine trial analysis. J Am Med Assoc 2003; 289:1491.
24. Montefiori DC, Metch B, McElrath MJ, et al. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004; 190:1962-1969.
25. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007; 196:1153-1162.
26. Kimman TG, Vandebriel RJ, Hoebee B. Genetic variation in the response to vaccination. Community Genet 2007; 10:201-217.
27. Newport MJ, Goetghebuer T, Weiss HA, et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun 2004; 5:122-129.
28. Lee YC, Newport MJ, Goetghebuer T, et al. Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins. Vaccine 2006; 24:5335-5340.
29. HohlerT, Reuss E, Evers N, et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002; 360:991-995.
30. Fellay J, Ge D, Shianna KV, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
31. PelakK, Goldstein DB, Walley NM, et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010; 201:1141-1149.
32. Kaslow RA, Rivers C, Tang J, et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001; 75:8681-8689.
33. Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010; 24:545-555.
34. Hung CC, Chang SY, Su CT, et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010; 11:54-63.
35. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48:659-666.
36. Livingston BD, Alexander J, Crimi C, et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999; 162:3088-3095.
37. Roenhorst HW, Kallenberg CG,TheTH.The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in nonimmunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetence. Clin Exp Immunol 1988; 74:326-332.
38. Karp CL, Wysocka M, Wahl LM, et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996; 273:228-231.
39. Eller LA, Eller MA, Ouma B, et al. Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS ONE 2008; 3:e3919.
40. Kibaya RS, Bautista CT, Sawe FK, et al. Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS ONE 2008; 3:e3327.
41. Harnett W, Harnett MM. Helminth-derived immunomodulators: can understanding the worm produce the pill? Nature Rev 2010; 10:278284.
42. van Riet E, Hartgers FC, Yazdanbakhsh M. Chronic helminth infections induce immunomodulation: consequences and mechanisms. Immunobiology 2007; 212:475-490.
43. van Riet E, Everts B, Retra K, et al. Combined TLR2 and TLR4 ligation in the context of bacterial or helminth extracts in human monocyte derived dendritic cells: molecular correlates for Th1/Th2 polarization. BMC Immunol 2009; 10:9.
44. Harn DA, McDonald J, Atochina O, Da'dara AA. Modulation of host immune responses by helminth glycans. Immunol Rev 2009; 230:247-257.
45. Goodridge HS, Marshall FA, Else KJ, et al. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62. J Immunol 2005; 174:284-293.
46. Melendez AJ, Harnett MM, Pushparaj PN, et al. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat Med 2007; 13:1375-1381.
47. Aksoy E, Zouain CS, Vanhoutte F, et al. Double-stranded RNAs from the helminth parasite Schistosoma activate TLR3 in dendritic cells. J Biol Chem 2005; 280:277-283.
48. Donnelly S, O'Neill SM, Stack CM, et al. Helminth cysteine proteases inhibit TRIF-dependent activation of macrophages via degradation of TLR3. J Biol Chem 2010; 285:3383-3392.
49. Da'dara AA, Harn DA. Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10. Vaccine 2010; 28: 1310-1317.
50. Harris JB, Podolsky MJ, Bhuiyan TR, et al. Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh. PLoS Negl Trop Dis 2009; 3:e403.
51. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118-129.
52. Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22:1493-1501.
53. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
54. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sexual Transm Dis 2008; 35:946-959.
55. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
56. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009:CD003362.
57. Chen L, Jha P, Stirling B, et al. Sexual riskfactors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLoS ONE 2007; 2:e1001.
58. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95.